Japan Covid Vaccine Packaging Market Size & Outlook, 2026-2034
Japan Covid Vaccine Packaging Market Insights
- Packaging Market Insights analysis indicates that the Japan Covid Vaccine Packaging Market size, valued at USD 83.2 Million in 2025, is expected to expand to USD 131.31 Million by 2034.
- The Japan market is forecasted to expand at a CAGR of 5.14% spanning 2026–2034.
- Glass Vials held the leading position among Product Type segments in 2025, based on market size.
- Glass Vials is projected to post the fastest growth rate, sustaining its position as the most attractive Product Type segment during the forecast horizon.
Source: PIAnalysis Company Publications, Primary Interviews.
Other Key Findings
- In 2025, Japan represented 3.06% of the overall global Covid Vaccine Packaging Market size.
- United States is projected to lead the global Covid Vaccine Packaging Market size by 2034.
- Across Asia Pacific, China is anticipated to hold the dominant position in market size by 2034.
- South Korea is forecasted to expand at the fastest pace in Asia Pacific, attaining USD 52.5 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 83.2 Million |
| Market Size In 2034 | USD 131.31 Million |
| Largest segment | Glass Vials |
| Units | Revenue in USD Million |
| CAGR | 5.14% (2026-2034) |
| Segmnetation Covered | |
| Product Type |
|
| Application |
|
| Distribution Channel |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Japan Covid Vaccine Packaging Market Product Type 2026-2034 (USD Million)
| Product Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glass Vials | XX.x | XX.x | XX.x | 38.6 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Prefilled Syringes | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Secondary Packaging | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: PIAnalysis Company Publications, Primary Interviews.
Japan Covid Vaccine Packaging Market Application 2026-2034 (USD Million)
| Application | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| mRNA Vaccines | XX.x | XX.x | XX.x | 39.01 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Viral Vector Vaccines | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Protein Subunit Vaccines | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: PIAnalysis Company Publications, Primary Interviews.
Japan Covid Vaccine Packaging Market Distribution Channel 2026-2034 (USD Million)
| Distribution Channel | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Direct Supply to Pharmaceutical Companies | XX.x | XX.x | XX.x | 31.18 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Medical & Pharmaceutical Distributors | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Government Procurement | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Hospital & Healthcare Networks | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Contract Packaging Organizations | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: PIAnalysis Company Publications, Primary Interviews.